ODDITY Tech Surges 11.57% on Q3 Earnings Beat and METHODIQ Launch – What’s Next for the Beauty Tech Giant?

Summary
• ODDITY Tech (ODD) surges 11.57% intraday to $41.46, up from $37.16 previous close
• Q3 revenue jumps 24% to $148M, adjusted EPS hits $0.40, exceeding guidance
• METHODIQ, a telehealth dermatology platform, launches as growth catalyst
• Options volatility spikes: 20 contracts traded, with ODD20251219C40 seeing 54,673 turnover

ODDITY Tech’s stock is in a tailwind after a blockbuster Q3 earnings report and the launch of its new telehealth brand, METHODIQ. The stock’s 11.57% surge reflects a mix of earnings optimism and strategic momentum. With a 24% revenue growth and raised full-year guidance, the company is positioning itself as a disruptor in both beauty and medical tech. Traders are now parsing technicals and options data to gauge the sustainability of this rally.

Q3 Earnings Beat and METHODIQ Launch Ignite ODDITY’s Rally
ODDITY’s 11.57% intraday surge stems from a combination of outperforming Q3 results and the strategic launch of METHODIQ, its telehealth dermatology platform. The company reported $148 million in revenue (+24% YoY), adjusted EPS of $0.40 (beating estimates of $0.35), and a 170-basis-point gross margin expansion to 71.6%. The launch of METHODIQ, targeting chronic skin conditions like acne and eczema, signals a pivot into high-growth medical tech, leveraging ODDITY’s data-driven brand-building expertise. Management’s raised full-year revenue guidance to $806–809 million and $2.10–2.12 adjusted EPS further underpins the bullish sentiment.

Personal Products Sector Rallying on Innovation, Estee Lauder Trails
The Personal Products sector is seeing renewed momentum as companies like ODDITY and Estee Lauder (EL) navigate innovation-driven growth. While ODDITY’s 11.57% surge reflects its dual focus on beauty and telehealth, Estee Lauder’s 0.31% intraday gain highlights the sector’s broader but more muted optimism. ODDITY’s strategy of integrating AI and telehealth into its brand ecosystem contrasts with EL’s traditional luxury cosmetics approach. The sector’s 2025 trends—sustainability, AI personalization, and inclusivity—are amplifying ODDITY’s disruptive edge, particularly in addressing unmet needs in dermatology and digital-first skincare.

Options and Technicals Signal High-Volatility Playbook for ODDITY Bulls
• RSI: 27.38 (oversold)
• MACD: -3.98 (bearish), Signal Line: -3.98 (neutral), Histogram: -0.006 (bearish divergence)
• Bollinger Bands: Upper $49.08, Middle $41.98, Lower $34.87 (current price near lower band)
• 200D MA: $56.64 (far above current price)
• Support/Resistance: 30D $51.03–51.33 (resistance), 200D $43.10–43.92 (potential support)

ODDITY’s technicals suggest a short-term rebound from oversold RSI levels but a long-term bearish trend amid a 200D MA gap. The stock’s intraday range ($40.10–$45.00) and 4.8% turnover rate indicate high volatility. For options traders, the ODD20251219C40 and ODD20251219C45 contracts stand out:

• ODD20251219C40 (Call):
- Strike: $40, Expiry: 2025-12-19
- IV: 66.26% (high volatility), Delta: 0.615 (moderate sensitivity), Theta: -0.0798 (rapid time decay), Gamma: 0.0486 (moderate sensitivity to price swings), Turnover: 54,673 (high liquidity)
- Payoff at 5% upside (43.53): $3.53/share. This contract offers aggressive leverage (10.61%) and liquidity, ideal for a short-term rally.

• ODD20251219C45 (Call):
- Strike: $45, Expiry: 2025-12-19
- IV: 54.65% (moderate), Delta: 0.3325 (low sensitivity), Theta: -0.0564 (moderate decay), Gamma: 0.0560 (high sensitivity), Turnover: 82,158 (very liquid)
- Payoff at 5% upside (43.53): $0.00 (strike not reached). While less immediately profitable, its high gamma and liquidity make it a safer bet for a gradual move above $45.

Aggressive bulls should prioritize ODD20251219C40 for a short-term pop, while ODD20251219C45 suits a more measured approach. Watch for a break above $45 to validate the rally.

Backtest ODDITY Tech Stock Performance
Hi— I attempted to pull historical prices for the ticker “ODD”, but the data provider returned an empty result set. That can happen if:1. The symbol is incorrect or has recently changed. 2. The stock was listed only after the start-date we requested. (Oddity Tech Ltd. – NASDAQ: ODD – went public on 19 Jul 2023, for example.) 3. The data vendor we’re accessing does not yet carry the instrument.To move the analysis forward, could you please confirm:• The exact ticker and listing exchange you’d like to test (e.g., “ODD” on NASDAQ, or a different symbol). • The earliest date from which you’d like the back-test to start (the IPO date, if it’s a recent listing, may be more appropriate than 2022). Once I have that confirmation I’ll retry the data pull and proceed with the event-study/back-test on +12 % intraday surges.

ODDITY’s Rally Hinges on METHODIQ Adoption and Earnings Momentum
ODDITY’s 11.57% surge is a testament to its Q3 outperformance and the strategic pivot into telehealth, but sustainability depends on METHODIQ’s traction and execution against raised guidance. The stock’s RSI at 27.38 suggests a short-term rebound, but the 200D MA gap and bearish MACD signal caution. For now, the ODD20251219C40 and ODD20251219C45 options offer high-leverage plays, while Estee Lauder’s 0.31% gain in the Personal Products sector underscores ODDITY’s disruptive edge. Watch for a close above $45 to confirm the breakout, and monitor Q4 guidance in December.